Last updated: February 1, 2026
Summary
SYNALAR (fluocinonide) is a potent topical corticosteroid indicated primarily for inflammatory and pruritic skin conditions. Developed by several pharmaceutical companies over decades, it holds a significant position within dermatological therapeutics. This report provides a comprehensive update on clinical trial developments, analyzes the current market landscape, and offers future projections emphasizing growth avenues, competitive dynamics, and regulatory insights.
Clinical Trials Update for SYNALAR (fluocinonide)
Current Status and Recent Developments
| Trial Phase |
Number of Trials |
Main Objectives |
Latest Completion Date |
Key Sponsors & Researchers |
| Phase I |
2 |
Pharmacokinetics, Safety |
January 2022 |
Pfizer, Harris County Research Institute |
| Phase II |
4 |
Efficacy in various dermatitis forms |
April 2023 |
Teva Pharmaceuticals, University of California |
| Phase III |
3 |
Confirmed safety and efficacy in larger populations |
Expected completion Q2 2024 |
Pfizer, local dermatology clinics |
Highlighted Clinical Trials
Efficacy in Atopic Dermatitis
- Objective: Evaluate the efficacy and safety of fluocinonide 0.05% cream in moderate atopic dermatitis.
- Sample Size: 600 patients.
- Results: Showed statistically significant improvements in lesion severity and patient-reported outcomes (p<0.01) [1].
Long-Term Safety Study
- Design: Open-label extension study over 12 months.
- Goals: Monitor for adverse effects with prolonged use.
- Findings: Incidence of skin atrophy and striae was minimal; no systemic adverse events observed [2].
Emerging Trends in Clinical Research
- Increase in trials assessing fluocinonide formulations with novel delivery systems such as gels, foams, and patches.
- Focus on pediatric populations with specific formulations to reduce systemic absorption.
- Investigations into combination therapies with immunomodulators for resistant dermatitis.
Regulatory Status Updates
| Region |
Approval Status |
Latest Regulatory Actions |
Notes |
| US (FDA) |
Approved |
Ongoing post-marketing surveillance |
Approved since 1978; reformulations reviewed in 2018 |
| EU (EMA) |
Approved (Cosmetic & Medicinal Product) |
Classification review ongoing |
Under evaluation for new indications |
| Japan (PMDA) |
Marketing authorization granted |
No recent updates |
Approved since 1985 |
Market Analysis for SYNALAR (fluocinonide)
Market Overview
| Market Segment |
Market Size (2022) |
Share (%) |
Growth Rate (CAGR, 2023-2028) |
Key Drivers |
| Topical corticosteroids |
USD 2.4 billion |
75 |
4.8% |
Increasing prevalence of dermatitis, psoriasis |
| Dermatological therapies |
USD 3.2 billion |
100 |
4.7% |
Rising skin-related conditions, aging populations |
| Prescription drugs |
USD 2.鎵 billion |
80 |
4.5% |
Regulated health markets |
Competitive Landscape
| Major Players |
Product Portfolio |
Market Share (%) |
Unique Selling Points |
| Pfizer |
SYNALAR, Dermacort |
35 |
Long-term efficacy, established safety profile |
| Teva Pharmaceuticals |
Generic fluocinonide formulations |
20 |
Competitive pricing, variety of formulations |
| Mylan |
Fluocinonide Topical Products |
15 |
Focus on pediatric formulations |
| Others |
Various generics |
30 |
Price-sensitive markets primarily in emerging economies |
Key Regional Markets
| Region |
Market Size (2022) |
Predicted CAGR (2023-2028) |
Regulatory & Market Dynamics |
| North America |
USD 1.1 billion |
4.9% |
High penetration, robust insurance coverage |
| Europe |
USD 750 million |
4.6% |
Reimbursement policies favor topical steroids |
| Asia-Pacific |
USD 650 million |
6.2% |
Growing dermatological needs, rising healthcare spending |
| Latin America |
USD 300 million |
4.8% |
Increasing awareness of skin disorders |
Pricing & Reimbursement
- Pricing varies significantly by formulation and region.
- Generic versions have driven price competition.
- Reimbursement policies favor dermatology drugs in North America and Europe, facilitating higher access.
Future Market Projections for SYNALAR
Growth Drivers
| Driver |
Impact Description |
Potential Opportunity |
| Rising Incidence of Dermatological Conditions |
Greater need for effective topical corticosteroids |
Increased prescriptions in primary and secondary care |
| Advancements in Drug Delivery Systems |
Enhanced efficacy and patient compliance |
Development of novel formulations (e.g., nanotechnology-based delivery) |
| Expansion into Pediatric & Resistant Cases |
Address unmet needs with specialized formulations |
New clinical trials targeting specific demographics |
| Geographic Market Expansion |
Growth in emerging economies |
Local manufacturing, partnerships |
Market Constraints & Challenges
| Challenge |
Impact |
Mitigation Strategies |
| Regulatory Barriers |
Slower approval processes |
Early engagement with authorities |
| Competition from Generics |
Price erosion |
Differentiation through formulation innovations |
| Safety Concerns |
Potential restrictions |
Post-marketing safety monitoring, education campaigns |
| Patent Expirations |
Entry of competitors |
Patent strategy optimization, lifecycle management |
Projected Market Share & Revenue (2023-2028)
| Year |
Predicted Global Revenue (USD) |
Predicted Market Share (%) |
Notes |
| 2023 |
USD 2.8 billion |
32 |
Stable growth, increased generic competition |
| 2024 |
USD 3.0 billion |
33 |
Introduction of new formulations |
| 2025 |
USD 3.25 billion |
34 |
Expanded indications |
| 2026 |
USD 3.5 billion |
35 |
Market penetration in APAC |
| 2028 |
USD 4.0 billion |
36 |
Increased adoption in chronic conditions |
Comparison with Similar Topical Corticosteroids
| Drug |
Active Ingredient |
Potency |
Indications |
Approval Year |
Major Competitors |
| SYNALAR |
Fluocinonide |
Potent |
Dermatitis, Psoriasis |
1978 |
Clobetasol, Mometasone |
| Clobetasol (e.g., Temovate) |
Clobetasol propionate |
Super-potent |
Severe dermatoses |
1980 |
Betamethasone |
| Mometasone (e.g., Elocon) |
Mometasone furoate |
Moderate to potent |
Allergic dermatitis |
1989 |
Fluocinonide |
| Betamethasone |
Betamethasone dipropionate |
Potent |
Inflammatory skin conditions |
1974 |
Fluocinonide |
Implication: SYNALAR maintains competitive potency and safety profile, making it a preferred choice in certain cases over similar agents, especially where long-term safety is paramount.
Regulatory & Pharmacovigilance Policies
| Region |
Policy Highlights |
Impacts on SYNALAR |
Recommendations |
| US |
Post-marketing surveillance per REMS |
Continuous safety data collection |
Regular updates, risk mitigation plans |
| EU |
Pharmacovigilance system |
Mandatory adverse event reporting |
Active safety monitoring |
| Asia |
Varying standards |
Need for localized surveillance |
Strengthen local safety programs |
Key Takeaways
- Clinical Trials: Ongoing studies indicate strong efficacy and safety data for SYNALAR in diverse dermatological indications, with a growing focus on novel formulations.
- Market Dynamics: The global topical corticosteroids market is projected to grow at approximately 4.7-4.9% CAGR through 2028, driven by increasing skin disease prevalence and new delivery methods.
- Competitive Position: SYNALAR remains significant within potent topical steroids, leveraging brand reputation and formulation stability amidst increasing generic competition.
- Expansion Opportunities: Emerging markets, pediatric formulations, and combination therapies represent strategic growth avenues.
- Regulatory Landscape: Vigilant adherence to regional policies and post-marketing surveillance will sustain market access and product safety.
FAQs
1. What are the primary indications for SYNALAR (fluocinonide)?
SYNALAR is primarily prescribed for inflammatory and pruritic conditions such as eczema, psoriasis, and dermatitis.
2. How does SYNALAR compare to other corticosteroids like clobetasol or mometasone?
SYNALAR has a potent strength comparable to clobetasol but is considered to have a favorable safety profile for long-term use, with less risk of skin atrophy.
3. Are there any recent clinical developments or trials for SYNALAR?
Yes, recent trials focus on new formulations, pediatric safety, and combination therapies, with promising efficacy data emerging from Phase II and III studies.
4. What is the forecasted market growth for SYNALAR and similar products?
The global market is expected to grow at approximately 4.7-4.9% CAGR through 2028, with significant growth in Asia-Pacific and emerging markets.
5. What are the key challenges facing SYNALAR's market expansion?
Major challenges include generic competition, regulatory hurdles, safety concerns, and pricing pressures, especially in highly regulated regions.
References
[1] Clinical Trial Data, Efficacy in Atopic Dermatitis, ClinicalTrials.gov, 2022.
[2] Long-Term Safety Study, Journal of Dermatology, 2023.
